In short
Tofersen, also known as BIIB067 or QALSODY, is an investigational drug being studied in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) associated with mutations in the superoxide dismutase 1 (SOD1) gene. These trials aim to evaluate the safety, efficacy, and long-term effects of Tofersen in both symptomatic and presymptomatic individuals with SOD1-ALS.
At a glance
- Drug Name
- Tofersen (also known as BIIB067 or QALSODY)
- Target Condition
- Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 mutations
- Administration Method
- Intrathecal injection
- Trial Phases
- Phase 1, 2, and 3 studies
- Key Objectives
- Evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics
- Primary Outcomes
- Changes in ALSFRS-R scores, adverse events, SOD1 protein levels
- Secondary Outcomes
- Slow vital capacity, muscle strength, neurofilament levels, time to death or permanent ventilation
- Study Populations
- Symptomatic ALS patients, presymptomatic SOD1 mutation carriers
- Trial Durations
- Ranging from 24 weeks to several years for long-term follow-up
What is Tofersen?
Tofersen, also known by its research names BIIB067 and QALSODY, is a promising new drug designed to treat a specific type of Amyotrophic Lateral Sclerosis (ALS). ALS is a severe neurological disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control. Tofersen is specifically targeted at ALS patients who have a mutation in the superoxide dismutase 1 (SOD1) gene.
How Tofersen Works
Tofersen works by targeting the root cause of SOD1-ALS. In patients with this type of ALS, the SOD1 gene produces abnormal proteins that can be toxic to nerve cells. Tofersen is designed to reduce the production of these harmful SOD1 proteins. By lowering the levels of toxic SOD1 proteins, Tofersen aims to slow down or potentially halt the progression of ALS in these patients.
Who Can Benefit from Tofersen?
Tofersen is specifically developed for people with ALS who have a confirmed mutation in the SOD1 gene. This includes:
- Patients already diagnosed with ALS and confirmed to have an SOD1 mutation
- Individuals who carry an SOD1 mutation but have not yet developed ALS symptoms (known as presymptomatic carriers)
It's important to note that SOD1-ALS represents only a small percentage of all ALS cases, typically around 2% of ALS patients.
How is Tofersen Administered?
Tofersen is administered through an intrathecal injection. This means the drug is injected directly into the fluid surrounding the brain and spinal cord. The typical dosing schedule includes:
- Initial loading doses: Given once every 2 weeks for the first month
- Maintenance doses: Given once every 4 weeks thereafter
This method of administration allows the drug to reach the central nervous system directly, where it can have the most impact on reducing SOD1 protein levels.
Clinical Trials and Research
Tofersen has been studied in several clinical trials:
- Phase 1/2/3 Trial (NCT02623699): This study evaluated the safety, effectiveness, and proper dosing of Tofersen in ALS patients with SOD1 mutations.
- Long-Term Extension Study (NCT03070119): This ongoing study is assessing the long-term safety and effectiveness of Tofersen in patients who participated in earlier trials.
- Presymptomatic Study (NCT04856982): This trial is investigating whether Tofersen can delay or prevent the onset of ALS symptoms in people who carry SOD1 mutations but haven't developed ALS yet.
These trials have shown promising results, including reductions in SOD1 protein levels and potential slowing of disease progression in some patients.
Safety and Side Effects
Like all medications, Tofersen can cause side effects. Common side effects observed in clinical trials include:
- Headache
- Back pain
- Post-lumbar puncture syndrome (headache, nausea, and dizziness after the injection)
- Fall
- Pain in extremity
Most side effects were mild to moderate in severity. However, as with any treatment involving spinal injections, there are risks of more serious complications. Patients should discuss all potential risks and benefits with their healthcare provider.
Future Prospects and Ongoing Research
Research on Tofersen is ongoing, with several exciting developments:
- Expanded Access Program: This program aims to provide Tofersen to eligible SOD1-ALS patients who cannot participate in clinical trials.
- Presymptomatic Treatment: Studies are investigating whether Tofersen can prevent or delay ALS onset in people with SOD1 mutations who haven't developed symptoms yet.
- Long-term Effects: Ongoing research is examining the long-term safety and effectiveness of Tofersen.
While Tofersen represents a significant step forward in treating SOD1-ALS, it's important to remember that research is ongoing, and the drug's long-term effects and benefits are still being studied.